Microchip (MCHP) Q4 2026 Earnings Transcript

Microchip Technology reported March-quarter revenue of $1.311 billion, up 35.1% year over year and above guidance, with non-GAAP EPS of $0.57 and adjusted EBITDA of $466.8 million. Management guided June-quarter sales up 11% sequentially (±1%) and highlighted stronger bookings, a higher backlog, and new data center design wins including six PCIe Gen6 wins and entry into the PCIe retimer market. Offsetting the upbeat outlook, the company warned that substrates and foundry capacity remain tight and that lead times are broadening.

Analysis

The setup is less about a single quarter beat and more about a synchronized inflection in channel, backlog, and supply tightness. That combination matters because it shifts the company from an inventory-destruction story to a lead-time expansion story, which tends to create duration in revenue and gives operating leverage a cleaner path than simple cyclical recovery. The market will likely underappreciate how much of the margin delta is being driven by utilization normalization rather than pricing, which makes the upside more durable if volume continues to stair-step higher.

The second-order effect is that tighter substrates and foundry nodes create a near-term moat for incumbents with broad qualification and legacy supply relationships, while pressuring smaller competitors and one-off sourcing strategies. In practice, that means the most valuable assets are not just the data center products themselves, but the ability to allocate scarce capacity across higher-value end markets and preserve customer mindshare during a supply squeeze. If lead times keep extending over the next 1-2 quarters, distributors may start ordering ahead of sell-through, which could temporarily inflate bookings and support an earnings revision cycle into summer.

The contrarian risk is that the story becomes too self-reinforcing: if management is right that demand is broadening while supply stays tight, the stock can rerate quickly, but the downside is a classic digestion phase if customers pull forward inventory and then pause. The main trigger to watch is whether June/September growth reflects true end-demand versus channel refill; if the former, this can trend for multiple quarters, but if the latter, the market will fade the tape once restocking peaks. Another risk is execution against a multi-segment ramp: the business has enough moving parts that any packaging, testing, or foundry slip could cap near-term upside even with strong demand.

Key Decisions for Investors

• Long MCHP into the next 4-8 weeks on any post-earnings consolidation; the risk/reward is attractive if the market starts pricing in sequential upside plus margin expansion, with likely 10-15% upside vs low-teens downside if supply tightness persists.
• Sell downside puts in MCHP 1-2 quarters out to monetize elevated implied vol; thesis is that earnings revisions and backlog growth provide a floor unless channel restocking proves synthetic.
• Pair trade: long MCHP / short a higher-beta analog peer with weaker supply-chain leverage (e.g., ADI or TXN on a relative basis) for the next 1-2 quarters; MCHP has a more explicit near-term catalyst stack from backlog, lead times, and mix improvement.
• Add a tactical long in a semiconductor equipment or test-name beneficiary only if management commentary confirms data-center test-capacity spend is rising; otherwise avoid chasing the capex angle because the current spend profile remains too maintenance-heavy to move the group.
• If MCHP gaps higher on the open, wait for a 3-5 day digestion and then buy strength only if channel checks show distributor restocking continuing; if sell-through stalls, fade the move with a short-dated put spread.